Loading stock data…
SANOFI (SAN.PA)
€75.50+0.43 (+0.57%)
Market ClosedLast close Jun 29
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sanofi in the Healthcare sector is trading at €75.50 with a market capitalization of $93.3B. Wall Street consensus targets €96.70 (23 analysts), implying a +28.1% move over the next 12 months. The stock is currently 17% below its 52-week high of €91.15, remaining 2.2% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +28.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (EUR) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | €10.61B↓ | €10.73B↓ | €13.17B↑ | €12.21B↑ | €11.24B |
| Gross Profit | €7.72B↓ | €7.74B↓ | €9.76B↑ | €8.45B↑ | €8.11B |
| Operating Income | €2.23B↑ | €1.71B↓ | €3.79B↑ | €1.63B↓ | €2.27B |
| Net Income | €1.87B↓ | €3.94B↑ | €2.80B↑ | -€801.00M↓ | €1.61B |
Peer Comparison
JNJUNHPFE
Fundamentals
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€93.30B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.68
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
539.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.58%
Volume
Today's trading volume
2.08M
Recent News
Deutsche Bank Cuts PT on Sanofi (SNY) – Here’s Why
Sanofi (NASDAQ:SNY) is one of the best low volatility stocks to buy under $50. Deutsche Bank cut the price target on Sanofi (NASDAQ:SNY) to EUR 95 from EUR 100 on June 15 and maintained a Buy rating on the shares. For reference, in its financial results for fiscal Q1 2026, Sanofi (NASDAQ:SNY) reported double-digit sales […]
BofA Expects Positive Investor Reaction to Leadership Update at Sanofi (SNY)
With an annual dividend yield of 5.79%, Sanofi (NASDAQ:SNY) is included among the 12 Best NASDAQ Stocks to Buy for Dividends. Sanofi (NASDAQ:SNY) is a healthcare biopharmaceutical company that engages in the research, development, manufacture, and marketing of therapeutic solutions. Sanofi (NASDAQ:SNY) announced on June 22 that it was appointing Dr Paulo Fontoura as its new […]
Sanofi Faces EU Probe With Fines Possibly Reaching 10%
EU regulators are investigating Sanofi over alleged misleading claims against CSL Seqirus' Fluad vaccine.
Sanofi Faces EU Antitrust Probe Over Flu Vaccine Communication Campaign
Sanofi (SNY) is facing an antitrust probe by the European Commission over a suspected breach of EU c
EU hits France's Sanofi with flu vaccine antitrust probe
The European Commission announced Friday that it was opening an antitrust probe into French pharmaceutical group Sanofi on suspicion it breached the bloc's competition rules in promoting a flu vaccine.Contacted by AFP, the group denied breaking EU rules.